Arcadia Biosciences Inc

Arcadia Biosciences Inc(RKDA)股票分析

$0.166

+0.005 (+3.05%)收盤時

Loading chart…
最高
0.171
開盤
0.165
成交量加權均價
0.16
成交量
121.01K
市值
4.25M
最低
0.154
成交金額
19.81K
企業價值/稅息折舊攤銷前利潤(TTM)
1.43

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.

AI 分析 of Arcadia Biosciences Inc (RKDA)

賣出

Arcadia Biosciences Inc (RKDA) is not a good buy right now due to its current price of $0.16, a year-to-date change of -92.52%, and a concerning forward P/E ratio of 36.63, indicating potential overvaluation despite the low stock price. The company is facing significant financial challenges, including a recent report of a Q4 GAAP EPS of -$0.97 and a revenue decline of 26.2% year-over-year, which raises serious doubts about its future profitability and growth potential.

分析師評級(1)

持有
0 買進
1 持有
0 賣出
目前: 0.17
最低
—
平均
—
最高
—

HC Wainwright & Co.

2024-08-21

目標價

$6

強烈買進

HC Wainwright & Co.

2024-05-23

目標價

$6

強烈買進

HC Wainwright & Co.

2024-04-05

目標價

$10

強烈買進

HC Wainwright & Co.

2023-08-28

目標價

$10

強烈買進

HC Wainwright & Co.

2023-07-24

目標價

$15

強烈買進

估值指標

Arcadia Biosciences Inc(RKDA)目前預期本益比為 36.63,5 年平均預期本益比為 5.54。

預期本益比

嚴重高估
5 年均值 P/E
5.54
目前P/E
36.63
高估
20.96
低估
-9.87

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
0.43
目前EV/EBITDA
1.43
高估
1.19
低估
-0.34

預期股價營收比

低估
5 年均值 P/S
0.85
目前P/S
0.05
高估
1.43
低估
0.26

Alphio AI 對 RKDA 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%RKDA

$5.40

情境價格

基

基準

基準 · 50%RKDA

$5.18

情境價格

悲

悲觀

悲觀 · 25%RKDA

$5.10

情境價格

事件時間軸

2026-06-26 (ET)

17:00:00

Arcadia Biosciences Files to Sell 11.92M Shares of Common Stock

2026-06-11 (ET)

21:00:00

Arcadia Biosciences Sells 3,883,496 Shares at $1.03 Each

2026-01-28 (ET)

06:10:00

Arcadia Biosciences Files to Sell 1.67M Shares of Common Stock

2026-01-20 (ET)

06:10:00

Rockwell Medical Sees Q4 Gross Margin Rise to 22%

2026-01-12 (ET)

08:50:00

Arcadia Biosciences Issues Preferred Investment Options, Raises Approximately $2.1M

資訊

RKDA 常見問題 —— 由 Alphio AI 解答

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour. It operates in the Consumer Non-Cyclicals sector.

Arcadia Biosciences Inc (RKDA) is not a good buy right now due to its current price of $0.16, a year-to-date change of -92.52%, and a concerning forward P/E ratio of 36.63, indicating potential overvaluation despite the low stock price. The company is facing significant financial challenges, including a recent report of a Q4 GAAP EPS of -$0.97 and a revenue decline of 26.2% year-over-year, which raises serious doubts about its future profitability and growth potential.

1 analysts cover RKDA: 0 rate it Buy, 1 Hold and 0 Sell.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易